Journals / Turkish Journal of Gastroenterology / 2001 / Cilt: 12 - Sayı: 2

Histolojik olarak resistan Helicobacter pylori enfeksiyonu saptanabilir mi? Gastrik histolojinin Helicobacter pylori enfeksiyonu eradikasyonu başarısına etkileri

Can resistant Helicobacter pylori infection be estimated histologically: Effects of gastric histology on eradication rates of Helicobacter pylori infection

Pages
126–129
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Results: The overall eradication rate was 59.5%.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Background/Aims: In spite of new drug regimens, the eradication of Helicobacter pylori infection remains problematic and factors interfering with therapeutic efficacy have yet to be clarified.
📊
Key Findings & Data:Methods: A total of 74 dyspeptic patients with Helicobacter pylori infection (45 men, 29 women; mean age 40 years) were included in the study.
💡
Conclusion & Impact:Results: The overall eradication rate was 59.5%.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Dispepsi · İlaç direnci · mikrobiyal

Abstract

Background/Aims: In spite of new drug regimens, the eradication of Helicobacter pylori infection remains problematic and factors interfering with therapeutic efficacy have yet to be clarified. In this study, the role of gastric histopathology in predicting resistant cases prior to therapy was investigated. Methods: A total of 74 dyspeptic patients with Helicobacter pylori infection (45 men, 29 women; mean age 40 years) were included in the study. Helicobacter pylori status was evaluated by histology and urease test at entry and four weeks after treatment. The Sydney system of gastric histology grading was applied to specimens taken from both the antrum and corpus to evaluate the severity of Helicobacter pylori -related gastritis. Eradication of the infection was defined as negative results of both tests. All patients received a two-week course of standard triple therapy (500 mg tetracycline qid and 750 mg metronidazole tid for two weeks and 300 mg bismuth subcitrate qid for four weeks). Results: The overall eradication rate was 59.5%. The eradication rate was different between patients with high, intermediate or low pretreatment gastritis activity (33%, 69 % and 58.8% respectively). The eradication rate of Helicobacter pylori in patients with lymphoid follicles in the antrum and corpus was similar to those without lymphoid follicles (63.6% vs 56.1%, p>0.05 and 57.8% vs 60%, p>0.05). Conclusion: This study suggests that cases of severe antral gastritis are resistant to eradication. Pretreatment histopathology may denote the success of eradication, determine the choice of regimen and predict cases of failed eradication.

Özet

Amaç: Yeni geliştirilen tedavi rejimlerine rağmen hala Helicobacter pylori enfeksiyonunu eradike etmek güçtür. Tedavi başarısını etkileyen faktörler tam belirlenememiştir. Ve biz bu çalışmada gastrik histolojinin tedaviye resistan olguların tedavi öncesi saptanmasındaki rolünü araştırmak istedik. Yöntem: Çalışmaya dispeptik yakınmaları olan Helicobacter pylori pozitif 74 (45'i erkek ve 29'u kadın, yaş ortalaması 40 yıl) olgu alındı. Helicobacter pylori varlığı hem çalışma başlangıcında hem de tedavi sonrası 4. haftada CLO testi ve histolojik olarak değerlendirildi. Antrum ve korpustan alınan patoloji spesmenlerindeki gastrit şiddeti Sydney sistemi ile değerlendirildi. Eradikasyon, her iki testinde negatifleşmesi ile pozitif olarak kabul edildi. Tüm olgulara 2 haftalık standart üçlü tedavi (Tetrasiklin 4X500 mg, Metranidazol 3X250 mg iki hafta ve bismuth subsitrat 4X300 mg 4 hafta) verildi. Bulgular: Eradikasyon oranı %59.5 idi. Eradikasyon oranı tedavi öncesi şiddetli, orta ve hafif gastritli olgularda istatiksel anlamlılığa ulaşılamamakla birlikte belirgin farklılık göstermekteydi (sırasıyla %33, %69, %58.8(p>0.05). Lenfoid follikül olan ve olmayan olgular arasında eradikasyon oranlarında farklılık yoktu. Sonuç: Bizim çalışmamız antral gastriti şiddetli olguların eradikasyona rezistan olgular olduğunu göstermektedir. Tedavi öncesi histolojik değerlendirme eradikasyon başarısının düşük olacağı olguları önceden saptamada etkin olabilir ve bu olgulara uygun rejimlerin seçilmesinde bize rehberlik edebilir.

🔖

Cite This Article

TAŞKIN, V., ÖZYILKAN, E., AYDIN, A., ÇETİN, F., ESKİOĞLU, E., KÖSEOĞLU, T. (2001). Histolojik olarak resistan Helicobacter pylori enfeksiyonu saptanabilir mi? Gastrik histolojinin Helicobacter pylori enfeksiyonu eradikasyonu başarısına etkileri. Turkish Journal of Gastroenterology, Cilt: 12 - Sayı: 2, 126–129. https://ajindex.com/articles/410936

References (16)

  1. Haas CE, Nix DE, Schentag JJ. In vitro selection of resistant Helicobacter pylori. Antimicrob. Agents Chemother. 1990; 34: 1637-41
  2. Marshall BJ. Helicobacter pylori: the etiologic agent for peptic ulcer. JAMA 1995; 274: 1064-6
  3. Stolte M, Eidt S. Helicobacter pylori and the evolution of gastritis. Scand J Gastroenterol 1996; 214: 13-6; discussion 21-3
  4. Marshall BJ,Goodwin CS, Warren JR, et al. Prospective double-blind trial of duodenal ulcer relapse after eradication of Campylobacter pylori. Lancet 1988; 2: 1437-42
  5. Graham DY, Lew GM, Klein PD, et al. Effect of treatment of Helicobacter pylori infection on the long-term recurrence of gastric or duodenal ulcer. A randomized, controlled study. Ann Intern Med 1992; 116: 705-8
  6. Bell GD, Powell KU, Burridge SM, et al. Reinfection or recrudescence after apparently successful eradication of Helicobacter pylori infection: implications for treatment of patients with duodenal ulcer disease. Q J Med 1993; 86: 375-82
  7. Tompkins DS, Perkin J, Smith C. Failed treatment of Helicobacter pylori infection associated with resistance to clarithromycin. Helicobacter 1997; 2: 185-7
  8. Matsumoto S, Washizuka Y, Matsumoto Y, et al. Appearance of a metronidazole-resistant Helicobacter pylori strain in an infected-ICR-mouse model and difference in eradication of metronidazole-resistant and –sensitive strains. Antimicrob Agents Chemother 1997; 41: 2602-5
  9. Bazzoli F, Pozzato P. Therapy of H. pylori infection. J Physiol Pharmacol 1997; 48: 39-46
  10. Price AB. The Sydney System: Histological division. J Gastroenterol Hepatol 1991; 6: 209-22
  11. Rinaldi V, Zullo A, Pugliano F, et al. The management of failed dual or triple therapy for Helicobacter pylori eradication. Aliment Pharmacol Ther 1997; 5: 929-33
  12. Graham DY, Lew G M, Malaty HM, et al. Factors influencing the eradication of Helicobacter pylori with triple therapy. Gastroenterology 1992; 102: 493-6
  13. Cutler AF, Schubert TT. Patient factors affecting Helicobacter pylori eradication with triple therapy. Am J Gastroenterol 1993; 88: 505-9
  14. Kamada T, Haruma K, Komoto K, et al. Effect of smoking and histological gastritis severity on the rate of H. pylori eradication with omeprazole, amoxicillin, and clarithromycin. Helicobacter 1999; 4: 204-10
  15. Warburton VJ, Everett S, Mapstone NP, et al. Clinical and histological associations of cagA and vacA genotypes in Helicobacter pylori gastritis. J Clin Pathol 1998; 51: 55-61
  16. Kearney DJ, Ritchie K,